



FREEDMAN



GELZER



HARTY

Anna Gelzer, Dr med vet, PhD, published Yaw TJ, Kraus MS, Ginsburg A, Hadfield CA, Gelzer AR*. Comparison of a Smartphone-Based Device with a Standard Six-Lead Electrocardiogram in the Atlantic Bottlenose Dolphin (*Tursiops truncatus*). *J Zoo Wildl Med.* 2018 Sep; 49(3):689-695. DOI: 10.1638/2017-0140.1. He also published Muñoz LM, Gelzer AR, Fenton FH, Qian W, Lin WY, Gilmour RF, Otani NF. Discordant Alternans as a Mechanism for Initiation of Ventricular Fibrillation In Vitro. *Journal of the American Heart Association.* Sep 4, 2018; 7(17): e007898. DOI: 10.1161/JAHA.117.007898.

Fuyu Guan, PhD, published Guan F, You Y, Li X, and Robinson MA. Detection and Confirmation of Alpha-cobrotoxin in Equine Plasma by Solid-Phase Extraction and Liquid Chromatography Coupled to Mass Spectrometry. *Journal of Chromatography A*, 1533: 38-48, 2018.

Karina Guzewicz, PhD, presented *Understanding the Dynamics of Subretinal Space in Health and Disease* at the 2018 International Society for Eye Research in Belfast, Ireland. She contributed a book chapter: Underdeveloped RPE Apical Domain Underlies Lesion Formation in Canine Bestrophinopathies (Guzewicz KE, McTish E, Dufour VL, Zorych K, Dhingra A, Boesze-Battaglia K, Aguirre GD. *Adv Exp Med Biol.* 2018;1074: 309-315).

Ronald Harty, PhD, Bruce Freedman, VMD, PhD, and collaborators at Fox Chase Chemical Diversity Center were issued a patent to develop novel small molecule, broad-spectrum therapeutics against viral infections caused by hemorrhagic fever viruses including Ebola, Marburg, and Lassa fever. Currently, there are no commercially available therapeutic agents for the treatment of these viral infections. The inhibitors target a virus-host interaction necessary for efficient virus egress from

infected host cells and are thus referred to as host-oriented inhibitors. The proposed anti-viral therapeutic that targets EBOV, MARV, and LAFV is being developed for treatment of infected individuals and for prophylactic treatment of soldiers, healthcare workers, or others at high risk. Emergency administration of such an antiviral therapeutic during an outbreak would inhibit virus dissemination within infected individuals and reduce infection of newly exposed individuals, thus slowing disease progression and transmission. Drs. Harty and Freedman are the co-founders of Intervir, a start-up company whose mission is to further develop and commercialize these antiviral therapeutics.

Christopher Hunter, PhD, was the invited guru and speaker at the NIH Immunology Retreat. He was also a joint organizer and speaker at the International Cytokine and Interferon Society meeting in Boston. He also spoke at the Brazilian Protozoological Society Annual Meeting in Brazil and the Yale Immunology Seminar Series. He took part in the Penn Vet Breakthrough Bike Challenge with **Molly Church, VMD, PhD**, and **Raimon Duran-Struuck, DVM, PhD**.

Meryl Littman, VMD, gave six hours of continuing education lectures about Lyme and other tick-borne diseases and leptospirosis in dogs in August 2018, at the Keystone Veterinary Conference in Hershey, Pennsylvania.

Carolina López, PhD, is a visiting professor at the Institut Pasteur, Paris, sabbatical funded by a US Scholar Fulbright award from November 2018 to April 2019. She was named Associate Editor of *PLoS Pathogens*. She published Genoyer E and López CB. *Distinct Intracellular Distribution of Full-Length and Defective Viral RNA Genomes Drives Functional Heterogeneity during Infection.* *J. Virol.* Nov 2018. DOI: 10.1128/JVI.01579-18.



Dr. David Holt Addresses Howard Hughes Medical Institute Medical Fellows.

David Holt, BVSc, gave the keynote speech at the 2018 Howard Hughes Medical Institute (HHMI) Medical Fellows Northeast Regional Meeting in Philadelphia.

HHMI supports scientists and educators to advance biomedical research and train the next generation of scientific leaders.

Holt is pictured with **Sabina Hlavaty, V'22**, co-chair of the meeting.